PSP5:PA:PA- (EUR)

ETF | Others |

Last Closing

USD 44.16

Change

+0.10 (+0.22)%

Market Cap

USD 0.42B

Volume

0.03M
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-26 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
JPX4:PA Amundi Index Solutions - Amund..

-0.06 (-0.13%)

USD 66.11B
SPY5:PA SPDR® S&P 500 UCITS ETF EUR

+1.60 (+0.31%)

USD 11.38B
WRD:PA HSBC ETFs Public Limited Compa..

+0.10 (+0.31%)

USD 9.27B
MEUD:PA Amundi Stoxx Europe 600 UCITS ..

-0.65 (-0.27%)

USD 7.87B
EQQQ:PA Invesco EQQQ NASDAQ-100 UCITS ..

+2.15 (+0.48%)

USD 7.42B
HHH:PA HSBC ETFs Public Limited Compa..

+0.15 (+0.30%)

USD 6.91B
WLD:PA Lyxor UCITS MSCI World D-EUR

+1.16 (+0.35%)

USD 6.48B
LCWD:PA Multi Units Luxembourg - Lyxor..

+0.05 (+0.27%)

USD 5.45B
SP5C:PA Lyxor S&P 500 UCITS ETF - C-EU..

+1.46 (+0.40%)

USD 4.39B
500U:PA Amundi Index Solutions - Amund..

+0.53 (+0.50%)

USD 4.29B

ETFs Containing PSP5:PA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 19.51% 88% B+ 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 19.51% 85% B 85% B
Trailing 12 Months  
Capital Gain 28.97% 85% B 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 28.97% 85% B 88% B+
Trailing 5 Years  
Capital Gain 113.36% 96% N/A 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 113.36% 96% N/A 93% A
Average Annual (5 Year Horizon)  
Capital Gain 15.26% 86% B+ 80% B-
Dividend Return 15.26% 82% B 78% C+
Total Return N/A 74% C 77% C+
Risk Return Profile  
Volatility (Standard Deviation) 14.58% 45% F 67% D+
Risk Adjusted Return 104.64% 99% N/A 96% N/A
Market Capitalization 0.42B 64% D 68% D+

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.